Strides Arcolab has got US health regulator’s approval for its Benzonatate softgel capsules that are used for treating cough caused by cold and other breathing problems such as pneumonia and asthma.
Strides Arcolab said in a BSE filing that the product will be launched immediately in the US market.
The company has received approval from the United States Food and Drug Administration (USFDA) for Benzonatate softgel capsules in the strengths of 100mg and 200 mg, it said.
“According to IMS data, the US market for Benzonatate is approximately USD 41 million,” the company said.
